Papillon-Cavanagh et al. analyzed the clinical efficacy of PD1/PD-L1 inhibitors or platinum-based chemotherapy against NSCLC with the double-mutational status in a real world-setting. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.